Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 3/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26615047 | 1.00 | SLC6A12 (0.35) | SLC6A12SLC6A11SLC6A13SIGABRR1 | |
| SCHEMBL26614925 | 1.00 | SLC6A12 (0.35) | SLC6A12SLC6A11SLC6A13SIGABRR1 | |
| SCHEMBL5773307 | 1.00 | SLC6A12 (0.35) | SLC6A12SLC6A11SLC6A13SIGABRR1 | |
| SCHEMBL2873601 | 1.00 | SLC6A12 (0.35) | SLC6A12SLC6A11SLC6A13SIGABRR1 | |
| SCHEMBL1586267 | 1.00 | SLC6A12 (0.35) | SLC6A12SLC6A11SLC6A13SIGABRR1 | |
| Hydrochloric Acid SCHEMBL21682454 | 0.98 | SLC6A12 (0.38) | SLC6A12SLC6A11SLC6A13SI | |
| SCHEMBL3372261 | 0.84 | POLB (0.32) | — | |
| SCHEMBL2908775 | 0.84 | POLB (0.32) | — | |
| SCHEMBL2908778 | 0.84 | POLB (0.32) | — | |
| SCHEMBL1924790 | 0.83 | SLC6A12 (0.35) | SLC6A12SLC6A11SLC6A13GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | SCHRIMPF MICHAEL R (US) | 2012-08-16 | — | — | US | disclosed |
| EP-1626973-B1 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE IS AN EFFECTIVE ANALGESIC AGENT | ABBOTT LAB (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-1771451-B1 | (1S,5S)-3-(5,6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE BENZENESULFONATE | ABBOTT LAB (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| US-7598236-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090198067-A1 | (1S,5S)-3-(5,6-Dichloropyridin-3-YL)-3,6-Diazabicyclo[3.2.0]Heptane Benzenesulfonate | ABBOTT LABORATORIES (US) | 2009-08-06 | — | — | US | disclosed |
| US-7498444-B2 | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate | ABBOOTT LABORATORIES (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2008-04-24 | — | — | US | disclosed |
| US-7351833-B2 | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate | ABBOTT LABORATORIES (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2006019668-A2 | (1S,5S)-3-(5,6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO[3.2.0]HEPTANE BENZENESULFONATE | ABBOTT LABORATORIES (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035937-A1 | (1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate | ABBVIE INC. | 2006-02-16 | — | — | US | disclosed |
| US-20050261348-A1 | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent | ABBOTT LABORATORIES | 2005-11-24 | — | — | US | disclosed |
| WO-2005028477-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS | ABBOTT LABORATORIES (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040242644-A1 | (IS-5S)-3-(5,6-dichloro-3-pyridinyl-)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent | ABBOTT LABORATORIES | 2004-12-02 | — | — | US | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| EP-1284976-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | SLC6A12 2965/4885SLC6A11 87/4885SLC6A13 96/4885 |
| US-20060035937-A1 | (1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate | DHPS, HCN2, DCPS | SLC6A12 649/4885SLC6A11 417/4885SLC6A13 320/4885 |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | SLC6A12 2965/4885SLC6A11 87/4885SLC6A13 96/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | SLC6A12 2879/4885SLC6A11 90/4885SLC6A13 97/4885 |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | SLC6A12 4747/4885SLC6A11 2677/4885SLC6A13 2883/4885 |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | SLC6A12 2965/4885SLC6A11 87/4885SLC6A13 96/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | SLC6A12 2879/4885SLC6A11 90/4885SLC6A13 97/4885 |
| US-20090198067-A1 | (1S,5S)-3-(5,6-Dichloropyridin-3-YL)-3,6-Diazabicyclo[3.2.0]Heptane Benzenesulfonate | DHPS, HCN2, DCPS | SLC6A12 649/4885SLC6A11 417/4885SLC6A13 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.